LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Suletud

SektorTervishoid

28.92 1.58

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

27.61

Max

29.01

Põhinäitajad
By Trading Economics
Sissetulek	11M 51M
Müük	39M 239M
P/E Sektori keskmine	8.476 108.767
Aktsiakasum	1.08
Kasumimarginaal	21.242
Töötajad	268
EBITDA	14M 73M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+44.53% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-140M 1.5B
Eelmine avamishind	27.34
Eelmine sulgemishind	28.92

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. märts 2026, 23:41 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2. märts 2026, 23:37 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2. märts 2026, 23:26 UTC

Uudisväärsed sündmused

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2. märts 2026, 22:41 UTC

Market Talk

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2. märts 2026, 22:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. märts 2026, 22:32 UTC

Market Talk

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2. märts 2026, 22:21 UTC

Market Talk

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2. märts 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

2. märts 2026, 22:11 UTC

Market Talk

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2. märts 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2. märts 2026, 22:06 UTC

Market Talk

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2. märts 2026, 22:00 UTC

Market Talk

Tulu

Global Forex and Fixed Income Roundup: Market Talk

2. märts 2026, 22:00 UTC

Market Talk

Tulu

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Energy & Utilities Roundup: Market Talk

2. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

2. märts 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

2. märts 2026, 21:35 UTC

Omandamised, ülevõtmised, äriostud

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2. märts 2026, 21:34 UTC

Omandamised, ülevõtmised, äriostud

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2. märts 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2. märts 2026, 21:17 UTC

Uudisväärsed sündmused

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2. märts 2026, 20:44 UTC

Tulu

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2. märts 2026, 20:43 UTC

Market Talk

Uudisväärsed sündmused

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2. märts 2026, 20:28 UTC

Tulu

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2. märts 2026, 20:25 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2. märts 2026, 20:24 UTC

Tulu

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2. märts 2026, 20:14 UTC

Omandamised, ülevõtmised, äriostud

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2. märts 2026, 20:12 UTC

Uudisväärsed sündmused

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2. märts 2026, 20:08 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

2. märts 2026, 20:08 UTC

Market Talk

Uudisväärsed sündmused

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2. märts 2026, 20:05 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

44.53% tõus

12 kuu keskmine prognoos

Keskmine 41.25 USD 44.53%

Kõrge 62 USD

Madal 25 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.